PPD

The Carlyle Group, Hellman & Friedman to acquire PPD

Tuesday, October 4, 2011 10:42 AM

Pharmaceutical Product Development (PPD) has entered into a definitive merger agreement under which it will be acquired by affiliates of The Carlyle Group and Hellman & Friedman in an all-cash transaction valued at $3.9 billion, after which PPD will be a private company.

More... »

New technology earns Quintiles top 5 ranking

Monday, October 3, 2011 08:00 AM

Many companies brag about bringing innovative technology to the clinical trials industry. Quintiles doesn’t have to brag. The most recent InformationWeek 500 is doing that for it.

More... »

PPD names CEO, puts acquisition rumors in question

Monday, September 26, 2011 08:02 AM

PPD has named a new CEO, a move that strikes some in the industry as a little strange in the face of rumors that the publicly traded CRO is close to selling itself to a private equity firm.

More... »

PPD names Hill CEO

Tuesday, September 20, 2011 10:14 AM

CRO PPD, which has been the subject of takeover speculation since July, has named Raymond Hill its new chief executive officer, filling a position that was vacant since mid-May, according to a PharmaTimes report.

More... »

Icon and Bristol-Myers Squibb build on strategic partnership, extending it to early-phase work

Monday, September 5, 2011 08:00 AM

Icon and Bristol-Myers Squibb (BMS) have inked a preferred-provider agreement for early-phase development. This constitutes the CRO’s second sizable agreement with BMS; in June 2010, the two formed a strategic partnership, with Icon focused on providing global support for the drug developer’s clinical development pipeline.

More... »

PPD rumored to be in exclusive acquisition talks with D.C.-based private equity firm the Carlyle Group

Monday, August 22, 2011 08:02 AM

While many in the upper echelon of private equity investors have been courting CRO PPD, for now all but one have been shooed away: Washington, D.C.-based Carlyle Group.

More... »

CROs using backlog numbers to put positive spin on less-than-stellar quarterly earnings reports

Monday, August 22, 2011 08:00 AM

Using backlog allows CROs to put a positive spin on what otherwise might be less-than-stellar earnings; while they may not have had the healthiest quarter—or year—financially, they can showcase all of the work that has been promised over the next few quarters in millions, or billions, of dollars.

More... »

PPD names chief scientific officer of BioDuro

Wednesday, August 17, 2011 11:43 AM

PPD has named Jasmine (Jisong) Cui, Ph.D., chief scientific officer of BioDuro, a PPD Company. Cui will provide scientific leadership to BioDuro's integrated drug discovery services across a range of disease areas and expand its use of novel technologies for small and large molecules and in stem cells and imaging.

More... »

Carlyle Group said to be in talks to buy PPD

Tuesday, August 16, 2011 12:59 PM

Carlyle Group is in exclusive talks to buy Pharmaceutical Product Development (PPD) a clinical research company, said five people with knowledge of the discussions, according to Bloomberg.

More... »

Ockham names Smith senior director

Wednesday, August 10, 2011 12:03 PM

Meghann Smith has joined Ockham as senior director, global therapeutic strategic development within the OckhamCROTM division. Smith will provide Ockham clients and functional teams with senior-level strategic guidance, risk mitigation analysis and solutions throughout the life-cycle of projects to help ensure study and program optimization on the regional, global and project/program levels with a primary therapeutic focus in hematology and oncology.

More... »